Abbott launched a smartphone-compatible next-gen insertable cardiac monitor (ICM) called Confirm Rx™ for more accurate remote monitoring of unpredictable heart rhythm problems. The small paperclip-sized implantable device offers more accurate detection of arrhythmia than traditional devices.
An arrhythmia is a problem with the rhythm of your heartbeat. The most common type of arrhythmia is atrial fibrillation, which causes an irregular and fast heartbeat. For the 33.5 million people living with atrial fibrillation (AFib)—the most common arrhythmia—many do not even know they have the condition.
The device is inserted just under the skin in the chest above the heart during a quick, minimally invasive outpatient procedure. It is the only ICM on the market that syncs to a smartphone via Bluetooth® and transmits information to the physician to help identify irregular heartbeats quickly. With the mobile app there’s no need for an additional transmitter. This user-friendly health technology is translated in nearly 40 languages, says a press release.
“Through new advances like Abbott’s next generation of Confirm Rx ICM, physicians can act more proactively and efficiently in their treatment approach, and patients can stay engaged and connected,” said Avi Fischer, M.D., medical director of Abbott’s Cardiac Rhythm Management therapies.
Currently available wearables for tracking cardiac arrhythmias have drawbacks when it comes to making a clinical diagnosis. Some require recharging at night while others require some level of interaction by the person to record symptoms. These may cause inaccurate data being delivered.
“Many of these devices still aren’t leading to an improved diagnosis or solving the key clinical challenges for people at risk,” said Sean Beinart, M.D., a cardiologist with Adventist Healthcare in Rockville, Md. “Like a guardian for heart health, Confirm Rx ICM can relay important data about a person’s heart rhythm through their smartphone and alert their care team to a potentially dangerous heart event. With Abbott’s new technology, I can better identify risk—making it actionable for me and life-changing for my patient.”
WT | Wearable Technologies Conference in San Francisco on July 9-10
Ismene Grohmann, Senior Director Innovation, Diabetes Care at Abbott, will be speaking about how data mosaics can help us better manage chronic diseases at the WT | Wearable Technologies Conference in San Francisco on July 9-10. The 34th edition of the WT | Wearable Technologies Conference Series is co-located to SEMICON West and topics include data analytics in professional sports, prevention, treatment and rehabilitation with wearables, the future of digital health, medication and adherence, smart patches, workflow optimization and workforce safety and much more – featuring international leaders and experts of the wearables industry´s biggest names including Abbott, Datwyler, Kopin, Maxim Integrated, Multek, NFLPA, Omron, SharkDreams, Qualcomm, and many more. Register now to be part of #WTUS19